Property:Exclusion criteria
This is a property of type Text.
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
previous history of peripheral neuropathy or with symptomatic peripheral neuropathy at entry into the study. We also excluded patients who had received other chemotherapy regimens (except 5-fluorouracil alone) and those currently receiving gabapentin, carbamazepine, amitriptyline, amifostine or multivitamins +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
Already taking a vitamin D supplement or active vitamin D; had a history of urinary tract stones; and other difficulties as judged by the surgeon in charge +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
History of previous malignancy or chemotherapy, history of other systemic diseases, metastatic condition or receiving other antiemetic drugs +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Previous or simultaneous radiotherapy in the head and neck region, including the nasopharynx, oropharynx, and larynx; previous head and neck surgery due to malignancy; use of dentures; pregnancy; infection +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
History of peripheral neuropathy (i.e., hereditary, paraneoplastic, or associated with nutritional agents) and a history of systemic diseases (i.e., diabetes mellitus, SLE, HIV, alcohol abuse); excluded if they were not chemotherapy-naïve or if clinical or electrophysiological evidence of peripheral neuropathy was disclosed at baseline +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
History of peripheral neuropathy (i.e., hereditary, paraneoplastic, or associated with nutritional agents) and a history of systemic diseases (i.e., diabetes mellitus, SLE, HIV, alcohol abuse); excluded if they were not chemotherapy-naïve or if clinical or electrophysiological evidence of peripheral neuropathy was disclosed at baseline +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
NI +
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients +
NI +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
Second malignancy within 5 years (excluding basal or squamous cell carcinoma of the skin treated curatively); brain metastasis; nephrolithiasis within 10 years; chronic hypercalcemia (i.e., serum calcium >1.0 mg/dL the upper limit of normal); chronic gastrointestinal disease (i.e., malabsorption, surgery affecting absorption, and chronic ulcerative colitis); urinary protein >4 g/24 h; urinary calcium ≥500 mg/24 h; active angina, New York Heart Association class II–IV heart failure, or history of myocardial infarction within 6 month; uncontrolled infection; or hypersensitivity to polysorbate 80, use of digitalis, thiazide diuretics, calcium supplements, anticonvulsants, fluoride, and lithium was not allowed, use of steroids was permitted unless taken for prostate cancer;
treatment with suramin, strontium, or other therapeutic radioisotopesor radiotherapy within 4 weeks +
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis +
Patients who were supposed to receive head and neck radiotherapy as part of their treatment, patients who were taking anticoagulant therapy, as some studies have shown that vitamin E may increase the bleeding tendency. +
B
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients +
- Karnofsky performance score of less than 60
- multiple primary head and neck cancers or a history of cancer
- severe cardiovascular disease
- inadequate renal, hepatic, or hematologic function
- anticoagulant therapy
- pregnancy
- average daily supplement intake of β-carotene or vitamin E in the preceding year greater than 6.0 mg and 50 IU, respectively +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
- Karnofsky performance score of less than 60
- multiple primary head and neck cancers or a history of cancer
- severe cardiovascular disease
- inadequate renal, hepatic, or hematologic function
- anticoagulant therapy
- pregnancy
- average daily supplement intake of β-carotene or vitamin E in the preceding year greater than 6.0 mg and 50 IU, respectively +
Bairati et al. (2006): Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients +
- Karnofsky performance score of less than 60
- multiple primary head and neck cancers or a history of cancer
- severe cardiovascular disease
- inadequate renal, hepatic, or hematologic function
- anticoagulant therapy
- pregnancy
- average daily supplement intake of β-carotene or vitamin E in the preceding year greater than 6.0 mg and 50 IU, respectively +
Barton et al. (1998): Prospective evaluation of vitamin E for hot flashes in breast cancer survivors +
Current or planned therapy with chemotherapy, androgens, estrogens, progestational agents, corticosteroids, or other agents used for treating hot flashes, intake of two multivitamin tablets per day or over 60 IU of vitamin E daily, pregnant or lactating women could not participate, nor could those with a history of bleeding tendencies, immune deficiencies, or thrombophlebitis +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
Use of Ginkgo biloba in the last 6 months; antithrombotic therapy; significant concomitant diseases, e.g. diabetes +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
Active malignancy within 5 years (except nonmelanoma skin cancer), significant active medical illness that would preclude protocol treatment, a history of hypercalcemia or vitamin D toxicity, or hospitalization for treatment of angina, myocardial infarction, or congestive heart failure in the previous 12 months;
kidney stones (calcium salt) within 5 years, hypersensitivity to calcitriol or drugs formulated with polysorbate-80, grade 2 or higher peripheral neuropathy, neutrophil count less than 1,500/mm<sup>3</sup> , platelet count lower than 100,000/ mm<sup>3</sup> , serum creatinine more than upper limit of normal (ULN), serum calcium more than ULN, conjugated bilirubin more than ULN, alkaline phosphatase more than 4 x ULN (patients with known bone involvement and a normal conjugated bilirubin, ALT, and AST were not excluded), ALT or AST more than 2.0 x ULN when alkaline phosphatase is less than 2.5 x ULN, ALT or AST more than 1.5 x ULN when alkaline phosphatase is more than 2.5 x ULN,
prior investigational therapy or use of calcitriol within 30 days, prior chemotherapy for prostate cancer except for adjuvant therapy more than 12 months before enrollment, prior chemotherapy with docetaxel, treatment with radiotherapy within 4 weeks or treatment with other radiopharmaceuticals within 8 weeks +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
Patients with symptomatic brain metastases;
- scheduled to receive or having received, in the past 4 weeks, radiotherapy to upper abdomen or craniospinal region;
- emesis or significant nausea within 24h before the first HEC cycle;
- coagulation disorders or current therapy with oral anticoagulants;
- planned surgery during the study period or within 2 weeks after its conclusion;
- prior seizures;
- cannabinoids or current/past drug or alcohol abuse;
- use of other investigational drug(s) within 30 days before study entry or during the study;
- any relevant condition potentially interfering with study evaluation;
- known hypersensitivity to ginger or any components of the product. +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
History of autoimmune disease, chronic inflammatory disease, active infectious diseases, liver or kidney disease, use of immunosuppressive drugs, or supplements containing zinc or copper, and chemotherapy or radiotherapy within 12 months before the study +
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
Previous treatment for HFS; hypersensitivity to pyridoxine; immunosuppression or positive human immunodefciency virus (HIV) serology +